AU Patent

AU2012241173B2 — Nucleoside Phosphoramidate Prodrugs

Assigned to Gilead Sciences Inc · Expires 2014-09-25 · 12y expired

What this patent protects

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline 5 form thereof, represented by the following struc…

USPTO Abstract

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline 5 form thereof, represented by the following structure: R3b IBase R3a N---P- O O C0 2 R4 ORI R \R 6 Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I. '7C 1

Drugs covered by this patent

Patent Metadata

Patent number
AU2012241173B2
Jurisdiction
AU
Classification
—
Expires
2014-09-25
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.